Amarin Raises Supply Issue Again On US Vascepa Generics
Originator Eschews 2021 Guidance Following Hikma Launch
With Hikma having launched the first generic version of Vascepa (icosapent ethyl) in the US last year, Amarin has again raised the issue of ANDA product supply for the complex purified fish oil brand.
You may also be interested in...
Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.